NPCE Quote, Financials, Valuation and Earnings

Ainos has a net margin of -29.25% compared to NeuroPace's net margin of -3093.98%. NeuroPace's return on equity of -186.98% beat Ainos's return on equity of -82.37%.

NeuroPace has a consensus price target of $17.13, signalling upside risk potential of 59.9%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that NeuroPace has higher upside potential than Ainos, analysts believe NeuroPace is more attractive than Ainos.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ainos has a beta of 2.202, suggesting its more volatile than the S&P 500 by 120.24%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $22.5M, which are larger than Ainos quarterly revenues of $106.2K. NeuroPace's net income of -$6.6M is lower than Ainos's net income of -$3.3M. Notably, NeuroPace's price-to-earnings ratio is -- while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.80x versus 56.59x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of -29.25% compared to NeuroPace's net margin of -348.97%. NeuroPace's return on equity of -186.98% beat Intelligent Bio Solutions's return on equity of -149.7%.

NeuroPace has a consensus price target of $17.13, signalling upside risk potential of 59.9%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 684.31%. Given that Intelligent Bio Solutions has higher upside potential than NeuroPace, analysts believe Intelligent Bio Solutions is more attractive than NeuroPace.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $22.5M, which are larger than Intelligent Bio Solutions quarterly revenues of $728.9K. NeuroPace's net income of -$6.6M is lower than Intelligent Bio Solutions's net income of -$2.5M. Notably, NeuroPace's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.80x versus 2.29x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -29.25% compared to NeuroPace's net margin of -63.81%. NeuroPace's return on equity of -186.98% beat Standard BioTools's return on equity of -26.52%.

NeuroPace has a consensus price target of $17.13, signalling upside risk potential of 59.9%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 99.58%. Given that Standard BioTools has higher upside potential than NeuroPace, analysts believe Standard BioTools is more attractive than NeuroPace.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.500, suggesting its more volatile than the S&P 500 by 50.042%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $22.5M, which are smaller than Standard BioTools quarterly revenues of $40.8M. NeuroPace's net income of -$6.6M is higher than Standard BioTools's net income of -$26M. Notably, NeuroPace's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.80x versus 2.62x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -29.25% compared to NeuroPace's net margin of -193.13%. NeuroPace's return on equity of -186.98% beat LENSAR's return on equity of -464.33%.

NeuroPace has a consensus price target of $17.13, signalling upside risk potential of 59.9%. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 17.56%. Given that NeuroPace has higher upside potential than LENSAR, analysts believe NeuroPace is more attractive than LENSAR.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $22.5M, which are larger than LENSAR quarterly revenues of $14.2M. NeuroPace's net income of -$6.6M is higher than LENSAR's net income of -$27.3M. Notably, NeuroPace's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.80x versus 2.60x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.